NWBO can easily move ten cents on some new information regarding management's plan for all solid tumors. The title tomorrow happens to be solid tumors not Glioblastoma. That implies more trials for additional indications as SEC 10Q/K make clear are management priorities. It implies management do not forsee issues with global approval for Glioblastoma.